Urology News and Research

Latest Urology News and Research

SBRT is effective for patients with low-to-intermediate-risk prostate cancer: Researchers

In a multicenter clinical trial, UT Southwestern Medical Center researchers have found that higher doses of stereotactic radiation therapy requiring fewer treatments are safe and effective for patients with low-to-intermediate-risk prostate cancer.

4 Jun 2011

Mount Sinai to participate in Medtronic CoreValve U.S. Clinical Trial

Mount Sinai Medical Center in Miami Beach, Florida announced its participation in the Medtronic CoreValve U.S. Clinical Trial, which will evaluate a new, non-surgical alternative to open-heart surgery for patients with severe aortic stenosis. Mount Sinai is now among a select number of leading hospitals across the U.S. to participate in this trial.

From Medtronic 4 Jun 2011

ZYTIGA clinical study data on prostate cancer to be presented at ASCO 2011

Data related to ZYTIGA (abiraterone acetate) will be presented at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

3 Jun 2011

APC8015F investigational vaccine improves survival of prostate cancer patients

Metastatic prostate cancer patients who received an investigational vaccine made from their own frozen immune cells lived 10 months longer than those not treated with it, according to data being presented by researchers from the Kimmel Cancer Center at Jefferson at the 2011 American Society of Clinical Oncology annual meeting in Chicago on Saturday, June 4.

3 Jun 2011

Stereotactic body radiation therapy effective for patients with low-risk prostate cancer

3 Jun 2011

Wireless near-infrared spectroscopy can effectively detect bladder disease in children

A cell phone-sized, wireless near-infrared device is as reliable as the current "gold standard" invasive tests in determining bladder disease, according to a study by researchers at the University of British Columbia, Vancouver Coastal Health and the Child & Family Research Institute (CFRI).

1 Jun 2011

FDA approves Oceana's Solesta for treatment of fecal incontinence

Oceana Therapeutics, a global company focused on acquiring, developing and commercializing best-in-class specialty therapeutics, announced that the U.S. Food and Drug Administration has approved Solesta as a treatment for fecal incontinence in adult patients who have failed conservative therapy such as dietary control.

31 May 2011

Oceana Therapeutics receives FDA approval for Solesta injectable gel to treat fecal incontinence

The U.S. Food and Drug Administration today approved a sterile, injectable gel to treat fecal incontinence in patients for whom other therapies such as diet change, fiber therapy or anti-motility medications failed.

30 May 2011

Hysterectomy procedures will continue to decline due to advantages of less-invasive alternatives: MRG

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, hysterectomy procedures as a treatment for menorrhagia and uterine fibroids will continue to decline at a rate of three percent a year through 2015. This decline is due to the growing advantages of less-invasive alternatives, primarily global endometrial ablation (GEA), and uterine artery embolization (UAE).

27 May 2011

Studies find antibiotics overused for children with asthma, urinary tract infections

Two new studies led by researchers at the University of California, San Francisco have found some antibiotics may be overused for children with asthma and urinary tract infections.

26 May 2011

Watson announces acquisition of Specifar Pharmaceuticals

Watson Pharmaceuticals, Inc. and Specifar Pharmaceuticals S.A. today jointly announced that Watson has acquired the privately-held multinational generic pharmaceutical developer, manufacturer and marketer for EUR 400 million in cash and certain contingent consideration.

25 May 2011

Positive interim results from new bladder cancer therapy trial

Clinical trials for a new bladder cancer therapy show promising interim results. Lead researcher Alvaro Morales says that the breakthrough using the drug Urocidin follows thirty years of his research in this important area.

25 May 2011

Galectin-3 research uncovers new use for Modified Citrus Pectin in cardiovascular, heart disease

In a new important research study out of the UK, scientists found that the specific form of Modified Citrus Pectin developed by Isaac Eliaz, M.D. interrupts deadly kidney fibrosis by binding to galectin-3 molecules, decreasing the effects of inflammation and fibrosis in acute kidney injury.

24 May 2011

MMP selects Online Tech for colocation services and offsite data storage, backup

Michigan Multispecialty Physicians, a specialty group of surgical physicians, has selected Online Tech, a premier Midwest managed data center provider, for colocation services and offsite data storage and backup.

24 May 2011

Exosome Diagnostics announces expansion of scientific advisory board

Exosome Diagnostics, a leading developer of biofluid based molecular diagnostic tests for use in personalised medicine, today announced the appointments of Bob Carter MD, Carlos Cordon-Cardo MD, PhD, Keith Flaherty MD, John Quackenbush, PhD; to its Scientific Advisory Board (SAB).

24 May 2011

PolyPid announces new drug delivery system and an innovative biodegradable bone void filler

PolyPid, a developer of innovative drug carriers, announced today the company’s flagship platform – PolyPid. PolyPid is a new, innovative family of drug carriers, based on a fusion between two known drug delivery systems: polymers and lipid-based systems. The new drug carriers enable long-lasting and controlled release of therapeutic drugs. The revolutionary, patented carrier can be tailored to almost any drug – small molecules, peptides, protein and nucleic acids-based drugs. The formulations can be pre-planned in order to achieve the desired release rate of the drug/s and the optimal duration, which can last up to several months.

23 May 2011

Sosei to introduce NorLevo oral emergency contraceptive in Japan

Sosei Group Corporation, the biopharmaceutical company, today announced that Sosei Co., Ltd., its wholly owned Japanese subsidiary, will launch its emergency contraceptive pill, NorLevo(R) TABLETS 0.75mg, tomorrow 24 May, through the distribution network of its commercialization partner, ASKA Pharmaceutical Co., Ltd.

23 May 2011

UM Board of Regents approves $13.7M renovation project for new health care policy institute

A new health care policy institute – one that is expected to become one of the largest of its kind in the nation – will be established at the University of Michigan's North Campus Research Complex.

21 May 2011

Decade-long study demonstrates immediate, long-term benefits of holmium laser treatment for enlarged prostate

New research presented at the Annual Meeting of the American Urology Association (AUA) in Washington, DC demonstrates that holmium laser therapy is a safe and durable treatment option for Benign Prostatic Hyperplasia (BPH) - an enlargement of the prostate that affects most men as they age.

21 May 2011

Advantagene reaches SPA agreement with FDA for ProstAtak Phase 3 trial to prevent prostate cancer recurrence

Advantagene, Inc., a Massachusetts-based biopharmaceutical company, announced today that it reached an agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment (SPA) for a pivotal Phase 3 clinical trial of ProstAtak™, its lead agent for patients with newly diagnosed prostate cancer.

19 May 2011

Urology News and Research

Latest Urology News and Research

SBRT is effective for patients with low-to-intermediate-risk prostate cancer: Researchers

Mount Sinai to participate in Medtronic CoreValve U.S. Clinical Trial

ZYTIGA clinical study data on prostate cancer to be presented at ASCO 2011

APC8015F investigational vaccine improves survival of prostate cancer patients

Stereotactic body radiation therapy effective for patients with low-risk prostate cancer

Wireless near-infrared spectroscopy can effectively detect bladder disease in children

FDA approves Oceana's Solesta for treatment of fecal incontinence

Oceana Therapeutics receives FDA approval for Solesta injectable gel to treat fecal incontinence

Hysterectomy procedures will continue to decline due to advantages of less-invasive alternatives: MRG

Studies find antibiotics overused for children with asthma, urinary tract infections

Watson announces acquisition of Specifar Pharmaceuticals

Positive interim results from new bladder cancer therapy trial

Galectin-3 research uncovers new use for Modified Citrus Pectin in cardiovascular, heart disease

MMP selects Online Tech for colocation services and offsite data storage, backup

Exosome Diagnostics announces expansion of scientific advisory board

PolyPid announces new drug delivery system and an innovative biodegradable bone void filler

Sosei to introduce NorLevo oral emergency contraceptive in Japan

UM Board of Regents approves $13.7M renovation project for new health care policy institute

Decade-long study demonstrates immediate, long-term benefits of holmium laser treatment for enlarged prostate

Advantagene reaches SPA agreement with FDA for ProstAtak Phase 3 trial to prevent prostate cancer recurrence

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Urology News and Research

Latest Urology News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in